Growth hormone axis

Follistatin

Name: Follistatin: What the Research Actually Shows
Creator: Peptide Health Lab

FOR RESEARCH PURPOSES ONLY

Also known as: Follistatin 344, FS344, FST

Regulatory status: Research only
Evidence grade: Animal studies only

Last reviewed September 1, 2026 · 13 sources

What follistatin is and how it works

Follistatin is not a peptide. It is a secreted glycoprotein of 315 or 344 amino acid residues, depending on the splice variant, and it works by physically trapping other proteins rather than by activating a receptor of its own. Its targets are ligands of the transforming growth factor-beta superfamily, activin A and myostatin among them, and myostatin is the reason anyone outside developmental biology has heard of it: myostatin is a secreted signal that normally limits skeletal muscle growth, so neutralizing it releases that brake.^[6]

The trapping mechanism is unusually well characterized for a compound in this category. The crystal structure of the follistatin:activin complex shows two follistatin molecules encircling a single activin dimer, burying roughly a third of its residues and covering its receptor-binding surfaces. The follistatin N-terminal domain turns out to adopt a fold that mimics a universal type I receptor motif, occupying that binding site as well — which was not what earlier work had predicted.^[8] The result is near-complete neutralization of the ligand, not partial inhibition.

Which splice variant is involved matters more than it sounds. FS288 binds heparin strongly and is therefore largely retained on cell surfaces, while FS315 carries an acidic C-terminal extension, circulates in serum, and has roughly ten-fold lower affinity for activin than FS288 does. The structure of the FS315-activin complex shows the C-terminal extension folded such that its acidic residues cannot reach the heparin-binding site — and that activin binding itself induces heparin binding in FS315, which the authors suggested may stimulate clearance of the complex.^[9] Clinical investigators chose the FS344 variant, which is post-translationally processed to the serum-based FS315 isoform, specifically because its lower activin affinity reduces the risk of interfering with the pituitary axis.^[3] A preparation with no isoform control has made none of those choices.

Follistatin's promiscuity is also its liability. Activin is a physiological driver of follicle-stimulating hormone release from the pituitary, so a potent activin antagonist is inherently a candidate FSH suppressant; that concern is stated in the clinical literature as the reason caution was called for from the outset.^[3] Follistatin additionally forms a stable complex with inhibin A, without interfering with its antagonism of activin A.^[10] This is a protein that sits in the middle of a reproductive endocrine circuit, and it is being discussed for its effect on muscle.

What the research actually shows

The human evidence is gene therapy, and it needs to be read as gene therapy. In a phase 1/2a proof-of-principle trial, six men with Becker muscular dystrophy received AAV1.CMV.FS344 — an adeno-associated viral vector carrying the FS344 gene — by direct bilateral intramuscular injection into the quadriceps. Three received 3 × 10¹¹ vector genomes per kilogram per leg and three received 6 × 10^11. On the six-minute walk test, the primary outcome, two participants in the first cohort improved by 58 and 125 metres and one showed no change; in the second cohort two improved by 108 and 29 metres and one did not. No adverse effects were encountered. Muscle biopsies showed reduced endomysial fibrosis, reduced central nucleation, and a more normal fibre size distribution with hypertrophy, most pronounced at the higher dose.^[1] A subsequent trial applied the same approach to sporadic inclusion body myositis and reported improved functional outcomes.^[2]

That is the entire human literature on follistatin, and the intervention it describes is a one-time injection of a virus that installs a gene in muscle fibres so those fibres manufacture the protein continuously and locally. It is not an injection of follistatin.

Animal work supports the muscle-mass mechanism, again through genetic delivery. AAV-mediated follistatin gene therapy improved functional outcomes in the TIC-DUX4 mouse model of facioscapulohumeral dystrophy.^[7] Reviews of myostatin inhibition have treated follistatin as one of the more potent available strategies for muscle disease.^[4]^[5]

One animal study is a direct warning against the simple version of the story. In dysferlin-deficient mice, in which membrane repair is compromised, follistatin transgene expression in skeletal muscle improved histopathology early and then exacerbated muscle degeneration. The same effect did not appear in dystrophin-deficient mdx mice, indicating the harm was specific to that disease context. Systemically administered soluble activin type IIB receptor in the same animals increased muscle mass and reduced fibrosis, yet raised serum creatine kinase in some of them, consistent with damage produced by the hypertrophy itself.^[6]

The analytical literature describes what circulating material actually contains. A doping-control laboratory obtained and analyzed seventeen products labeled as follistatin 344 or 315. Nine contained follistatin. Several of the remaining products contained different growth-promoting peptides — mechano growth factor and GHRP-2 among them. All nine of the genuine ones contained histidine-tagged FS344 together with a high degree of its oligomers, an expression tag and aggregation state that permit unambiguous discrimination from endogenous follistatin.^[11] Endogenous serum follistatin in healthy volunteers sits below 5 nanograms per millilitre.^[12]

Where the evidence is weak

Gene therapy and protein injection are not the same intervention, and the gap between them is the whole page. AAV gene transfer places a gene inside muscle fibres that then express follistatin locally and continuously, at the site where the effect is wanted, from a single procedure. An injected protein preparation delivers a bolus of exogenous glycoprotein into tissue, where it is subject to distribution, binding, and clearance — and where its activity depends on which isoform it is, whether it is correctly folded and glycosylated, and whether it has aggregated. Follistatin's own biochemistry makes that last point sharp: isoform identity governs whether the protein stays at cell surfaces or circulates, and activin binding itself appears to promote clearance of the circulating complex.^[9] No published study reports the pharmacokinetics of an injected follistatin preparation in a human, so there is no basis for stating how long any such exposure would last.

Not one human has received an injected follistatin preparation in a published study. There is no trial, no dose-finding work, no case series, and no adverse-event record for the thing people actually discuss. Every human number associated with this compound belongs to a viral vector delivered into a quadriceps muscle in a patient with a progressive genetic muscle disease. Any review characterizing unapproved compounds in this class describes exactly this kind of evidence vacuum.^[13]

The gene therapy trials are themselves small and unblinded. Six patients, open-label, no placebo group, no randomization, in a disease whose six-minute walk test varies substantially between visits, with two of six showing no change.^[1] The follow-up study in inclusion body myositis shares that design.^[2] These are legitimate early-phase results and they are appropriately described as proof of principle by their own authors. They are not efficacy evidence, and they are certainly not efficacy evidence about a different intervention in a different population.

Hypertrophy is not the same as improvement. The dysferlinopathy result is the clearest available demonstration that adding muscle mass can make an outcome worse, and reviews of myostatin-targeting drug development describe a broader pattern in which increases in muscle mass have repeatedly failed to convert into functional gains.^[6]^[5] The hypertrophy story that attaches to follistatin in popular discussion consistently skips the part where the field kept failing to show that hypertrophy helped.

The endocrine off-target is real, not hypothetical. Suppression of follicle-stimulating hormone through the pituitary activin-inhibin axis was enough of a concern that clinical investigators selected an isoform partly to avoid it, and follistatin's stable complex formation with inhibin A is further evidence of how embedded this protein is in reproductive signaling.^[3]^[10] Nobody has measured what an uncontrolled preparation of unverified isoform does to gonadotropins in a person.

Identity is unresolved in a documented, quantified way. Roughly half the analyzed products did not contain the protein their labels named, and the ones that did carried an expression tag and substantial oligomerization.^[11] Very few compounds on this site have a published figure attached to the identity question. This one does, and it is not reassuring.

Legal and regulatory status

Follistatin is not approved by the FDA for any indication, and no regulator has approved a follistatin product anywhere. A search of approved drug products returns no application with follistatin as an active ingredient, and the doping-control literature states the position directly: no approved pharmaceutical formulations of follistatin are available.^[11] Material carrying the name is distributed for laboratory research use, which is why every mention of it on this site carries research-only framing. The clinical work that does exist is investigational gene therapy conducted under trial protocols.^[1]

In tested sport the status is settled. Follistatin is prohibited under chapter S4 of the World Anti-Doping Agency list as a myostatin-inhibiting protein.^[11] Detection is operational rather than theoretical: complementary assays combining immunoaffinity purification, tryptic digestion and LC-HRMS/MS with confirmatory Western blotting distinguish synthetic follistatin constructs from naturally occurring isoforms at an estimated limit around 10 nanograms per millilitre, well above the endogenous serum concentration in healthy volunteers.^[12] Where material carries a histidine tag, that tag alone permits unambiguous identification.^[11]

What the regulatory status means for a reader is narrower and more useful than any argument about enforcement: there is no label, no approved manufacturer, no assigned indication, and no regulated quality standard behind anything carrying this name. PHL does not sell peptides and takes no position on how unapproved material reaches anyone.

Questions to bring to a provider

The useful conversation is not "how would I run follistatin." Given that the only human evidence is a gene therapy trial in a genetic muscle disease, the honest question is whether anything in that literature applies to the situation at hand at all. Questions worth raising:

The published human results come from a virus delivering a gene into muscle fibres. What is the reasoning that connects that to an injected protein, and does it survive scrutiny?^[1]
Given that no human has received an injected follistatin preparation in any published study, what would count as evidence that it did anything, and what would count as evidence that it was safe?^[13]
Follistatin suppresses follicle-stimulating hormone through the pituitary activin-inhibin axis. If fertility or hormonal status matters here, what baseline and follow-up testing would detect a change?^[3]
Is there any reason to think added muscle mass is the actual goal, given that in at least one disease model hypertrophy accelerated degeneration and that myostatin-targeting programmes have repeatedly failed to convert mass into function?^[6]^[5]
For an unapproved protein where roughly half of analyzed products did not contain what their labels claimed, how would anyone confirm what a given preparation actually is?^[11]
If competing in a tested sport, what does the current prohibited list say, and what are the consequences of a positive finding?^[12]

A clinician who answers "the human evidence is gene therapy and this is not gene therapy" has identified the central problem with this compound.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Muscle mass or strength gain in humans from an injected follistatin preparation

Anecdotal reports only review

No human evidence exists for the injected preparation. Not one published trial, controlled study, open-label series, or case report has administered a follistatin protein by injection to a person and measured muscle mass, strength, or function. Every human result associated with this compound comes from gene therapy, which is a categorically different intervention, and reviews of unapproved compounds in this class describe the human evidence as scarce.

[13] [3]

Functional improvement from AAV-delivered follistatin gene therapy

Anecdotal reports only human observational · review

This is the real human evidence, and it is gene therapy, open-label, and tiny. Six men with Becker muscular dystrophy received AAV1.CMV.FS344 by direct bilateral intramuscular quadriceps injection in a phase 1/2a proof-of-principle trial. Four improved on the six-minute walk test, by 58, 125, 108 and 29 metres; two showed no change. Muscle biopsies showed reduced endomysial fibrosis, reduced central nucleation, and more normal fibre size distribution with hypertrophy, particularly at the higher dose. No adverse effects were encountered. A follow-up trial reported improved functional outcomes in sporadic inclusion body myositis. Both were unrandomized and unblinded with no placebo group, in progressive diseases where a six-minute walk test is a variable measure — which is why the grade here is anecdotal despite the trials being real and carefully conducted.

[1] [2] [3]

Antagonism of activin and myostatin signaling

Animal studies only in vitro

The mechanism is genuinely well characterized, structurally. The crystal structure of the follistatin:activin complex shows two follistatin molecules encircling activin, burying about a third of its residues and its receptor binding sites, with the N-terminal domain adopting a fold that mimics a type I receptor motif and occupies that binding site as well. A later structure of the FS315-activin A complex quantified how the two splice isoforms differ in heparin binding, which governs whether the protein is retained at cell surfaces or circulates. Follistatin also forms a stable complex with inhibin A without interfering with its activin antagonism. This is structural biology and biochemistry, not evidence of a clinical effect.

[8] [9] [10]

Muscle hypertrophy in animal models

Animal studies only animal · review

Blocking the myostatin pathway increases skeletal muscle mass in animals, and follistatin is one of the more potent ways to do it. AAV-mediated follistatin gene therapy improved functional outcomes in the TIC-DUX4 mouse model of facioscapulohumeral dystrophy, and reviews of myostatin inhibition treat follistatin as a leading candidate for muscle-wasting disease. In every case the delivery is genetic — a transgene or a viral vector producing the protein continuously inside muscle — not an injected protein, and the animals are models of disease.

[7] [4] [5]

Hypertrophy translating into benefit

Animal studies only animal · review

Explicitly contradicted in at least one context. In dysferlin-deficient mice, follistatin transgene expression improved histopathology early and then accelerated muscle degeneration, an effect absent in mdx mice. Systemic activin type IIB receptor treatment in the same model increased muscle mass and reduced fibrosis while raising serum creatine kinase in some animals. The authors' conclusion is the relevant one: the potential gains from myostatin blockade have to be weighed against detrimental effects that depend on the disease context. Reviews of myostatin-targeting drug development describe a field where increases in muscle mass have repeatedly failed to convert into functional gains.

[6] [5]

Long-term safety in humans

Anecdotal reports only review · human observational

Unknown for the injected preparation, and only narrowly characterized for gene therapy in a handful of patients with specific muscle diseases. The one mechanism-derived concern that is well established rather than speculative is the pituitary one: follistatin's interaction with the activin-inhibin axis and its capacity to suppress follicle-stimulating hormone was significant enough to shape which isoform clinical investigators were willing to use.

[3] [2]

Claim area	Evidence & sources	What the research shows
Muscle mass or strength gain in humans from an injected follistatin preparation	Anecdotal reports only review [13] [3]	No human evidence exists for the injected preparation. Not one published trial, controlled study, open-label series, or case report has administered a follistatin protein by injection to a person and measured muscle mass, strength, or function. Every human result associated with this compound comes from gene therapy, which is a categorically different intervention, and reviews of unapproved compounds in this class describe the human evidence as scarce.
Functional improvement from AAV-delivered follistatin gene therapy	Anecdotal reports only human observational · review [1] [2] [3]	This is the real human evidence, and it is gene therapy, open-label, and tiny. Six men with Becker muscular dystrophy received AAV1.CMV.FS344 by direct bilateral intramuscular quadriceps injection in a phase 1/2a proof-of-principle trial. Four improved on the six-minute walk test, by 58, 125, 108 and 29 metres; two showed no change. Muscle biopsies showed reduced endomysial fibrosis, reduced central nucleation, and more normal fibre size distribution with hypertrophy, particularly at the higher dose. No adverse effects were encountered. A follow-up trial reported improved functional outcomes in sporadic inclusion body myositis. Both were unrandomized and unblinded with no placebo group, in progressive diseases where a six-minute walk test is a variable measure — which is why the grade here is anecdotal despite the trials being real and carefully conducted.
Antagonism of activin and myostatin signaling	Animal studies only in vitro [8] [9] [10]	The mechanism is genuinely well characterized, structurally. The crystal structure of the follistatin:activin complex shows two follistatin molecules encircling activin, burying about a third of its residues and its receptor binding sites, with the N-terminal domain adopting a fold that mimics a type I receptor motif and occupies that binding site as well. A later structure of the FS315-activin A complex quantified how the two splice isoforms differ in heparin binding, which governs whether the protein is retained at cell surfaces or circulates. Follistatin also forms a stable complex with inhibin A without interfering with its activin antagonism. This is structural biology and biochemistry, not evidence of a clinical effect.
Muscle hypertrophy in animal models	Animal studies only animal · review [7] [4] [5]	Blocking the myostatin pathway increases skeletal muscle mass in animals, and follistatin is one of the more potent ways to do it. AAV-mediated follistatin gene therapy improved functional outcomes in the TIC-DUX4 mouse model of facioscapulohumeral dystrophy, and reviews of myostatin inhibition treat follistatin as a leading candidate for muscle-wasting disease. In every case the delivery is genetic — a transgene or a viral vector producing the protein continuously inside muscle — not an injected protein, and the animals are models of disease.
Hypertrophy translating into benefit	Animal studies only animal · review [6] [5]	Explicitly contradicted in at least one context. In dysferlin-deficient mice, follistatin transgene expression improved histopathology early and then accelerated muscle degeneration, an effect absent in mdx mice. Systemic activin type IIB receptor treatment in the same model increased muscle mass and reduced fibrosis while raising serum creatine kinase in some animals. The authors' conclusion is the relevant one: the potential gains from myostatin blockade have to be weighed against detrimental effects that depend on the disease context. Reviews of myostatin-targeting drug development describe a field where increases in muscle mass have repeatedly failed to convert into functional gains.
Long-term safety in humans	Anecdotal reports only review · human observational [3] [2]	Unknown for the injected preparation, and only narrowly characterized for gene therapy in a handful of patients with specific muscle diseases. The one mechanism-derived concern that is well established rather than speculative is the pituitary one: follistatin's interaction with the activin-inhibin axis and its capacity to suppress follicle-stimulating hormone was significant enough to shape which isoform clinical investigators were willing to use.

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

Phase 1/2a open-label gene transfer trial in six men with Becker muscular dystrophy — a viral vector carrying the follistatin gene delivered by direct bilateral intramuscular injection into the quadriceps, not an injected protein

Two cohorts received 3 × 10^11 and 6 × 10^11 vector genomes per kilogram per leg of AAV1.CMV.FS344. This is a dose of virus, and it is not convertible into a dose of protein by any published relationship [1]
Endogenous serum follistatin measured in healthy volunteers during development of a doping-control assay, reported as a baseline reference rather than as an administered amount

Below 5 nanograms per millilitre, consistent with published reference values and below the detection limit of the doping-control methods being validated [12]

No published study of any species has established a dose for an injected follistatin protein preparation. Every human number above comes from a gene therapy trial, where the intervention is a viral vector delivering a gene to muscle fibers, or from a measurement of what the body already makes. The milligram figures that circulate in community discussion have no published study behind them and are therefore not reported here.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

No human safety data for any injected follistatin preparation

Not established · The published human safety record belongs to gene therapy: a handful of participants receiving a viral vector by intramuscular injection, in whom no adverse effects were encountered over the trial period. That record says nothing about repeated systemic injection of a follistatin protein preparation, which no published study has ever administered to anyone. A 2026 review characterizes the human safety and efficacy data for unapproved peptides and proteins in this class as scarce, with potential for serious harm.

[1] [13]
Suppression of follicle-stimulating hormone via the pituitary axis

A recognized concern that shaped the design of clinical constructs · Follistatin binds activin, and activin is a physiological driver of follicle-stimulating hormone secretion from the pituitary. Its ability to interact with the pituitary activin-inhibin axis and suppress FSH is explicitly cited as the reason caution was called for in clinical development, and it is why trials used the FS344 variant, which is processed to the serum-based FS315 isoform with roughly ten-fold lower activin affinity than FS288. Follistatin also forms a stable complex with inhibin A. A preparation with no isoform control and no manufacturing standard has none of the mitigation the clinical constructs were designed around. Anyone with a fertility concern, or on any hormonal therapy, has a reason to raise this with a clinician.

[3] [10]
Hypertrophy that worsens outcomes in the wrong disease context

Demonstrated in one mouse model, absent in another · This is the most instructive safety finding in the literature because it shows that more muscle is not automatically better. In dysferlin-deficient mice, whose membrane repair is compromised, follistatin transgene expression in skeletal muscle produced early histopathological improvement and then ultimately exacerbated muscle degeneration. The same effect was not seen in dystrophin-deficient mdx mice. Systemic administration of a soluble activin type IIB receptor to the same dysferlin-deficient animals increased muscle mass and reduced fibrosis but raised serum creatine kinase in some, suggesting damage induced by the hypertrophy itself. The authors concluded that the effects of myostatin blockade are disease-context dependent.

[6]
Unverified identity of material carrying this name

Documented in the majority of products in one analysis · A doping-control laboratory analyzed seventeen products labeled as follistatin 344 or follistatin 315. Only nine contained follistatin. Some of the others contained different growth-promoting peptides entirely, including mechano growth factor and GHRP-2. All nine that did contain follistatin carried a histidine-tagged construct along with a high degree of oligomers — a recombinant expression tag and aggregation state that have no place in a therapeutic protein and that made the material distinguishable from endogenous follistatin by antibody. With no approved manufacturer, nothing guarantees that a vial holds the protein its label names.

[11]
Prohibited in tested sport

Standing status · Follistatin is prohibited under chapter S4 of the World Anti-Doping Agency list as a myostatin-inhibiting protein. Detection assays now exist: immunoaffinity purification with liquid chromatography and high-resolution tandem mass spectrometry, plus Western blotting that distinguishes synthetic constructs from naturally occurring isoforms, with an estimated detection limit around 10 nanograms per millilitre in serum and plasma. In the case of tagged material, the tag itself permits unambiguous differentiation from endogenous follistatin. Any athlete in a tested sport should confirm the current year's prohibited list rather than rely on this page.

[12] [11]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage: Lyophilized protein preparations of this class are conventionally kept refrigerated at 2–8 °C and protected from light, with freezing used for long-term holding and repeated freeze-thaw cycling avoided. That convention comes from general recombinant-protein practice. No published stability study addresses any follistatin preparation intended for injection.
Reconstituted storage: Once in solution, recombinant glycoproteins are conventionally refrigerated at 2–8 °C, protected from light, and treated as short-dated. Follistatin is a 344- or 315-residue glycoprotein rather than a short peptide, and larger proteins are more prone to aggregation in solution than small peptides are. No published study establishes a solution shelf life for this compound.
Reconstitution diluent: The conventional diluent for lyophilized research proteins is bacteriostatic water: sterile water preserved with 0.9% benzyl alcohol. Sterile water without a preservative is used where a preservative is contraindicated and is treated as single-use.
Reconstitution & handling: Conventional handling: sanitize the stopper before piercing it, add the diluent slowly down the inside wall of the vial rather than directly onto the powder, and let it dissolve on its own. Swirl gently if needed; never shake, because proteins of this size are shear-sensitive and prone to aggregation. A properly reconstituted solution is clear; anything cloudy, discolored, or carrying visible particulate is discarded. PHL does not publish volume or unit calculations, because those are dosing decisions and dosing decisions belong with a licensed clinician.
Handling notes: There is no approved manufacturer, so there is no label, no assigned beyond-use date, and no lot-level stability testing behind any storage claim. Aggregation is a documented problem here rather than a theoretical one: when a doping-control laboratory analyzed seventeen products labeled as follistatin 344 or 315, only nine contained follistatin at all, and all nine of those contained a histidine-tagged construct together with a high degree of its oligomers. Treat everything above as convention, not specification.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

13 sources · every identifier checked against PubMed

[1] A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy · Molecular Therapy, 2015. Human observational study
[2] Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes · Molecular Therapy, 2017. Human observational study
[3] Follistatin gene therapy improves ambulation in Becker muscular dystrophy · Journal of Neuromuscular Diseases, 2015. Review
[4] Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease · Muscle & Nerve, 2009. Review
[5] Myostatin: basic biology to clinical application · Advances in Clinical Chemistry, 2022. Review
[6] Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy · Human Molecular Genetics, 2015. Animal study
[7] AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD · JCI Insight, 2018. Animal study
[8] The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding · Developmental Cell, 2005. In vitro study
[9] Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions · The Journal of Biological Chemistry, 2007. In vitro study
[10] Follistatin forms a stable complex with inhibin A that does not interfere with activin A antagonism · Endocrinology, 2023. In vitro study
[11] Detection of black market follistatin 344 · Drug Testing and Analysis, 2019. In vitro study
[12] Detection of follistatin-based inhibitors of the TGF-beta signaling pathways in serum/plasma by means of LC-HRMS/MS and Western blotting · Drug Testing and Analysis, 2020. In vitro study
[13] Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance · Sports Medicine, 2026. Review

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder